<?xml version='1.0' encoding='utf-8'?>
<document id="24132772"><sentence text="An open-label drug-drug interaction study of the steady-state pharmacokinetics of topiramate and glyburide in patients with type 2 diabetes mellitus."><entity charOffset="82-92" id="DDI-PubMed.24132772.s1.e0" text="topiramate" /><entity charOffset="97-106" id="DDI-PubMed.24132772.s1.e1" text="glyburide" /><pair ddi="false" e1="DDI-PubMed.24132772.s1.e0" e2="DDI-PubMed.24132772.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24132772.s1.e0" e2="DDI-PubMed.24132772.s1.e1" /></sentence><sentence text="Topiramate is approved for epilepsy and migraine headache management and has potential antidiabetic activity"><entity charOffset="0-10" id="DDI-PubMed.24132772.s2.e0" text="Topiramate" /></sentence><sentence text=" Because topiramate and antidiabetic drugs may be co-administered, the potential drug-drug interactions between topiramate and glyburide (glibenclamide), a commonly used sulfonylurea antidiabetic agent, was evaluated at steady state in patients with type 2 diabetes mellitus (T2DM)"><entity charOffset="9-19" id="DDI-PubMed.24132772.s3.e0" text="topiramate" /><entity charOffset="112-122" id="DDI-PubMed.24132772.s3.e1" text="topiramate" /><entity charOffset="127-136" id="DDI-PubMed.24132772.s3.e2" text="glyburide" /><entity charOffset="138-151" id="DDI-PubMed.24132772.s3.e3" text="glibenclamide" /><entity charOffset="170-182" id="DDI-PubMed.24132772.s3.e4" text="sulfonylurea" /><pair ddi="false" e1="DDI-PubMed.24132772.s3.e0" e2="DDI-PubMed.24132772.s3.e0" /><pair ddi="false" e1="DDI-PubMed.24132772.s3.e0" e2="DDI-PubMed.24132772.s3.e1" /><pair ddi="false" e1="DDI-PubMed.24132772.s3.e0" e2="DDI-PubMed.24132772.s3.e2" /><pair ddi="false" e1="DDI-PubMed.24132772.s3.e0" e2="DDI-PubMed.24132772.s3.e3" /><pair ddi="false" e1="DDI-PubMed.24132772.s3.e0" e2="DDI-PubMed.24132772.s3.e4" /><pair ddi="false" e1="DDI-PubMed.24132772.s3.e1" e2="DDI-PubMed.24132772.s3.e1" /><pair ddi="false" e1="DDI-PubMed.24132772.s3.e1" e2="DDI-PubMed.24132772.s3.e2" /><pair ddi="false" e1="DDI-PubMed.24132772.s3.e1" e2="DDI-PubMed.24132772.s3.e3" /><pair ddi="false" e1="DDI-PubMed.24132772.s3.e1" e2="DDI-PubMed.24132772.s3.e4" /><pair ddi="false" e1="DDI-PubMed.24132772.s3.e2" e2="DDI-PubMed.24132772.s3.e2" /><pair ddi="false" e1="DDI-PubMed.24132772.s3.e2" e2="DDI-PubMed.24132772.s3.e3" /><pair ddi="false" e1="DDI-PubMed.24132772.s3.e2" e2="DDI-PubMed.24132772.s3.e4" /><pair ddi="false" e1="DDI-PubMed.24132772.s3.e3" e2="DDI-PubMed.24132772.s3.e3" /><pair ddi="false" e1="DDI-PubMed.24132772.s3.e3" e2="DDI-PubMed.24132772.s3.e4" /></sentence><sentence text="" /><sentence text="This was a single-center, open-label, phase I, drug interaction study of topiramate (150 mg/day) and glyburide (5 mg/day alone and concomitantly) in patients with T2DM"><entity charOffset="73-83" id="DDI-PubMed.24132772.s5.e0" text="topiramate" /><entity charOffset="101-110" id="DDI-PubMed.24132772.s5.e1" text="glyburide" /><pair ddi="false" e1="DDI-PubMed.24132772.s5.e0" e2="DDI-PubMed.24132772.s5.e0" /><pair ddi="false" e1="DDI-PubMed.24132772.s5.e0" e2="DDI-PubMed.24132772.s5.e1" /></sentence><sentence text=" The study consisted of 14-day screening, 48-day open-label treatment, and a 7-day follow-up phase" /><sentence text=" Serial blood and urine were obtained and analyzed by liquid chromatography coupled mass spectrometry/mass spectrometry for topiramate, glyburide, and its active metabolites M1 (4-trans-hydroxy-glyburide) and M2 (3-cis-hydroxy-glyburide) concentrations"><entity charOffset="124-134" id="DDI-PubMed.24132772.s7.e0" text="topiramate" /><entity charOffset="136-145" id="DDI-PubMed.24132772.s7.e1" text="glyburide" /><entity charOffset="209-236" id="DDI-PubMed.24132772.s7.e2" text="M2 (3-cis-hydroxy-glyburide" /><pair ddi="false" e1="DDI-PubMed.24132772.s7.e0" e2="DDI-PubMed.24132772.s7.e0" /><pair ddi="false" e1="DDI-PubMed.24132772.s7.e0" e2="DDI-PubMed.24132772.s7.e1" /><pair ddi="false" e1="DDI-PubMed.24132772.s7.e0" e2="DDI-PubMed.24132772.s7.e2" /><pair ddi="false" e1="DDI-PubMed.24132772.s7.e1" e2="DDI-PubMed.24132772.s7.e1" /><pair ddi="false" e1="DDI-PubMed.24132772.s7.e1" e2="DDI-PubMed.24132772.s7.e2" /></sentence><sentence text=" Pharmacokinetic parameters were estimated by model-independent methods" /><sentence text=" Changes in fasting plasma glucose from baseline and safety parameters were monitored throughout the study"><entity charOffset="27-34" id="DDI-PubMed.24132772.s9.e0" text="glucose" /></sentence><sentence text="" /><sentence text="Of 28 enrolled patients, 24 completed the study" /><sentence text=" Co-administration of topiramate resulted in a significant (p &lt; 0"><entity charOffset="22-32" id="DDI-PubMed.24132772.s12.e0" text="topiramate" /></sentence><sentence text="05) decrease in the glyburide area under the concentration-time curve (25 %) and maximum plasma concentration (22 %), and reduction in systemic exposure of M1 (13 %) and M2 (15 %)"><entity charOffset="20-29" id="DDI-PubMed.24132772.s13.e0" text="glyburide" /></sentence><sentence text=" Renal clearance of M1 (13 %) and M2 (12 %) increased during treatment with topiramate"><entity charOffset="76-86" id="DDI-PubMed.24132772.s14.e0" text="topiramate" /></sentence><sentence text=" Steady-state pharmacokinetics of topiramate were unaffected by co-administration of glyburide"><entity charOffset="34-44" id="DDI-PubMed.24132772.s15.e0" text="topiramate" /><entity charOffset="85-94" id="DDI-PubMed.24132772.s15.e1" text="glyburide" /><pair ddi="false" e1="DDI-PubMed.24132772.s15.e0" e2="DDI-PubMed.24132772.s15.e0" /><pair ddi="false" e1="DDI-PubMed.24132772.s15.e0" e2="DDI-PubMed.24132772.s15.e1" /></sentence><sentence text=" Co-administration of topiramate and glyburide was generally tolerable in patients with T2DM"><entity charOffset="22-32" id="DDI-PubMed.24132772.s16.e0" text="topiramate" /><entity charOffset="37-46" id="DDI-PubMed.24132772.s16.e1" text="glyburide" /><pair ddi="false" e1="DDI-PubMed.24132772.s16.e0" e2="DDI-PubMed.24132772.s16.e0" /><pair ddi="false" e1="DDI-PubMed.24132772.s16.e0" e2="DDI-PubMed.24132772.s16.e1" /></sentence><sentence text="" /><sentence text="Glyburide did not affect the pharmacokinetics of topiramate"><entity charOffset="0-9" id="DDI-PubMed.24132772.s18.e0" text="Glyburide" /><entity charOffset="49-59" id="DDI-PubMed.24132772.s18.e1" text="topiramate" /><pair ddi="false" e1="DDI-PubMed.24132772.s18.e0" e2="DDI-PubMed.24132772.s18.e0" /><pair ddi="false" e1="DDI-PubMed.24132772.s18.e0" e2="DDI-PubMed.24132772.s18.e1" /></sentence><sentence text=" Co-administration of topiramate decreased systemic exposure of glyburide and its active metabolites; combined treatment may require dosing adjustments of glyburide as per clinical judgment and glycemic control"><entity charOffset="22-32" id="DDI-PubMed.24132772.s19.e0" text="topiramate" /><entity charOffset="64-73" id="DDI-PubMed.24132772.s19.e1" text="glyburide" /><entity charOffset="155-164" id="DDI-PubMed.24132772.s19.e2" text="glyburide" /><pair ddi="false" e1="DDI-PubMed.24132772.s19.e0" e2="DDI-PubMed.24132772.s19.e0" /><pair ddi="false" e1="DDI-PubMed.24132772.s19.e0" e2="DDI-PubMed.24132772.s19.e1" /><pair ddi="false" e1="DDI-PubMed.24132772.s19.e0" e2="DDI-PubMed.24132772.s19.e2" /><pair ddi="false" e1="DDI-PubMed.24132772.s19.e1" e2="DDI-PubMed.24132772.s19.e1" /><pair ddi="false" e1="DDI-PubMed.24132772.s19.e1" e2="DDI-PubMed.24132772.s19.e2" /></sentence><sentence text="" /></document>